Navigation Links
Cephalon Announces FDA Advisory Committee Recommendation Against Approval of an Expanded Label for FENTORA
Date:5/6/2008

Cephalon to Hold Conference Call with Investors Today at 5:30 p.m. EDT

FRAZER, Pa., May 6 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) announced today that a Joint Advisory Committee to the U.S. Food and Drug Administration (FDA) voted not to recommend approval of an expanded label for FENTORA(R) (fentanyl buccal tablet) [C-II] for the management of breakthrough pain in opioid-tolerant patients with chronic pain conditions. The panel expressed concerns about minimizing risks potentially associated with an expanded indication of FENTORA. During the meeting, the company presented a comprehensive and novel Risk Minimization Action Plan (RiskMAP) to address these risks.

FDA action on the FENTORA supplemental new drug application (sNDA) is expected by September 13, 2008. FENTORA is currently indicated for the management of breakthrough pain in opioid-tolerant patients with cancer.

"We are disappointed with the recommendation of the Advisory Committee," said Dr. Lesley Russell, Executive Vice President, Worldwide Medical and Regulatory Operations at Cephalon. "We will work with the FDA over the next few months to determine future steps including any additional risk minimization strategies that could potentially address the panel's concerns in this broader patient population."

The recommendation of the Joint Advisory Committee for Anesthetic and Life Support Drugs and the Advisory Committee for Drug Safety and Risk Management was based upon data presented by Cephalon from three randomized clinical trials and one 18-month open-label safety study with a total of 941 patients. The Joint Advisory Committee also considered proposed enhancements to the FENTORA RiskMAP that are designed to assure appropriate patient selection and to mitigate the risks of overdose, abuse, and diversion.

The FDA considers the Committee's recommendation in its review of the sNDA for FENTORA, which was submitted by Cephalon in November 2007. The FDA
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Cephalon Conference Call Invitation
2. Cephalon Reports Strong First Quarter Earnings
3. Cephalon Appoints Gerald J. Pappert as General Counsel
4. inVentiv Selling Solutions Selected to Provide Sales Team for Cephalon Inc.
5. Cephalon to Present at the 26th Annual JP Morgan Healthcare Conference
6. Cephalon Appoints Valli F. Baldassano as Executive Vice President and Chief Compliance Officer
7. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
8. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
9. Mergent, Inc. Announces Changes to the HealthShares(TM) Composite, Enabling Technologies, Autoimmune-Inflammation, Cancer, Cardiology and Neuroscience Indexes
10. WebMD Announces First Quarter Financial Results
11. HLTH Corporation Announces First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/26/2014)... It is said that nothing makes a lady ... famous wedding dress supplier, shows its new selection of ... promotion. , UWDress.com’s navy cocktail gowns are the cornerstones ... high fashion styles. Simple dresses in bright neon colors can ... are specially designed for those who want to shine among ...
(Date:12/26/2014)... (PRWEB) December 26, 2014 “Many people ... with personal injury claim issues and phone calls with ... released an article featuring their free eBook on ... helpful eBook on pedestrian and bicycle auto accident claims ... is fully capable of professionally handling their case while ...
(Date:12/25/2014)... (PRWEB) December 26, 2014 The ... CAGR of 7.2% to reach $5,756.0 million by ... the microscopy market. The electron microscopes product segment ... the forecast period. , Rising focus on nanotechnology, ... growth of the microscopy market. , Get Full ...
(Date:12/25/2014)... York (PRWEB) December 25, 2014 Product ... DePuy ASR hip recall ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to ... According to an Order issued in the U.S. District ... Court will convene an open conference on January 7, ... United States Courthouse in West Palm Beach, Florida. The ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 Recently, ... discounts on all its wedding dresses. BellasDress has chosen ... more for gift choices for the holiday season. ... can pick suitable wedding gowns here at discount prices. ... shopping experience at its website. , “All ...
Breaking Medicine News(10 mins):Health News:UWDress.com Shows Its New Navy Cocktail Dresses For 2015 2Health News:Guide to Handling Pedestrian and Bicycle Accidents Released By The Jones Firm, Featured in Recent Article 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2
... be further explored, researchers say , TUESDAY, Nov. 17 ... likely to die after admission to the hospital with ... suggests. , "After admission to a hospital, trauma ... the study authors wrote. "This concerning finding warrants more ...
... show need for improvement , TUESDAY, Nov. 17 (HealthDay ... job of reducing preterm births, according to a new ... high numbers of early, life-threatening deliveries. , , Vermont ... preterm birth rate under 10 percent, while in Louisiana, ...
... BEACH, Calif., Nov. 17 With these tough economic times, ... gifting this year. Imagine being able to donate to ... and overworked feet. Yoga Sandals® Footwear by Beech Sandal ... feet flexible with 20% of each purchase donated to a ...
... ... working is emerging as the top business objective for employer-sponsored wellness programs around the ... New ... is emerging as the top business objective for employer-sponsored wellness programs around ...
... XOWii is continuing ... was launched in early October, has met with much success. XOWii Thin is looking to ... healthy weight control. , ... November 16, 2009 --The XOWii company has made it their vision to be at the ...
... ... a total settlement of $3.25 million for two sanitation workers whose garbage truck was hit by ... Barnes lawyer Michael Cooper. , ... (Lexis Nexis) November 17, 2009 -- New York law firm Cellino & Barnes ...
Cached Medicine News:Health News:Uninsured Trauma Patients More Likely to Die: Study 2Health News:U.S. Scores a 'D' on Preterm Birth Report Card 2Health News:U.S. Scores a 'D' on Preterm Birth Report Card 3Health News:U.S. Scores a 'D' on Preterm Birth Report Card 4Health News:Give a Gift that Gives Back With Yoga Sandals(R) Comfys 2Health News:Wellness Survey: Businesses Look to Wellness Programs to Improve Productivity and Lower Absenteeism Stress Cited as Top Health Risk Driving Wellness Programs Around the World 2Health News:Wellness Survey: Businesses Look to Wellness Programs to Improve Productivity and Lower Absenteeism Stress Cited as Top Health Risk Driving Wellness Programs Around the World 3Health News:Wellness Survey: Businesses Look to Wellness Programs to Improve Productivity and Lower Absenteeism Stress Cited as Top Health Risk Driving Wellness Programs Around the World 4Health News:Wellness Survey: Businesses Look to Wellness Programs to Improve Productivity and Lower Absenteeism Stress Cited as Top Health Risk Driving Wellness Programs Around the World 5Health News:Wellness Survey: Businesses Look to Wellness Programs to Improve Productivity and Lower Absenteeism Stress Cited as Top Health Risk Driving Wellness Programs Around the World 6Health News:XOWii Launches Second Product in its Line of What are Proving to be Impeccably Designed and Unique Products 2Health News:New York Personal Injury Law Firm Cellino & Barnes Wins $3.25 Million Settlement For Workers Injured in Truck Accident 2
(Date:12/24/2014)...  Actavis plc (NYSE: ACT ) ... complete response letter from the U.S. Food and ... (NDA) for the fixed-dose combination (FDC) of nebivolol ... Photo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO ... of a complete response letter, Actavis remains committed ...
(Date:12/24/2014)... 2014 /PRNewswire/  -- Tianyin Pharmaceutical Inc. (NYSE Amex: ... specializes in the patented biopharmaceutical, modernized traditional Chinese ... (API) released unaudited preliminary financial results for the ... Fiscal Year 2015 Ended September 30, 2014 Financial ... with $14.7 million in 1Q14 with gross margins ...
(Date:12/24/2014)... 24, 2014 Soligenix, Inc. (OTCQB: SNGX) ... developing products that address unmet medical needs in ... today that on December 24, 2014 it closed ... The Company raised approximately $2.3 million in gross ... the net proceeds from the offering to fund ...
Breaking Medicine Technology:Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3
... from a Phase III,clinical trial evaluating the efficacy ... the treatment of postmenopausal osteoporosis were,presented at the ... Annual Meeting. In the non-inferiority study comparing risedronate ... [Actonel(R) (risedronate sodium,tablets)] increases in bone mineral density ...
... Medical,Technologies, Inc. (Nasdaq: RMTI ), a ... specialty pharmaceuticals focused on the end-,stage-renal-disease market ... in its Phase IIb dose-ranging study for ... drug. The Phase IIb dose-ranging study ...
Cached Medicine Technology:New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis 2New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis 3New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis 4New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis 5New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis 6Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study 2Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study 3Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study 4
... Releasing the power of clinical information. ... newest generation of clinical connectivity solutions that ... provide effective, high-quality patient care. You will ... be able to share it with your ...
... tool for Clinical Professionals and Researchers., ,S/5 ... easy and efficient way to collect data from ... to days at selectable time intervals. With S/5 ... from the monitor via an interface cable or ...
... Flexible monitoring for intermediate care., ,The ... GE Healthcare Datex-Ohmeda S/5 product line., ,The ... you the power to grow. The new Patient ... hemodynamic measurements up to 12-lead ECG, NIBP, ...
... ,The Datex-Ohmeda S/5 Light Monitor is a ... and critical care areas, in emergency or medium-care ... part of the Datex-Ohmeda S/5 family, the S/5 ... and design shared by all S/5 monitoring products ...
Medicine Products: